Pfizer Aktie News

Pfizer's stock has experienced significant fluctuations in the past 4 years, with opportunities for investors to buy low and sell high. The market has driven Pfizer's price to a 10-year low. Pfizer's focus on oncology and its strong pipeline of new products position the company for future growth, although debt obligations may limit dividend increases in the short term.

Pfizer Inc has agreed to settle more than 10,000 cases about cancer risks related to the now discontinued heartburn drug Zantac, Bloomberg News reported on Wednesday, citing people familiar with the deal.

Often overlooked, especially in times of AI revolution, the healthcare market is always a safe bet for investors, as it is a multiple trillion, highly innovative industry with no drawbacks like lack of demand per se.

Johnson & Johnson is a steady portfolio stalwart. Abbott Labs has exciting growth opportunities ahead.

A young boy died due to a cardiac arrest in a mid-stage trial that tested Pfizer's experimental gene therapy for a muscle-wasting disorder called Duchenne muscular dystrophy (DMD), the drugmaker told Reuters on Tuesday.

In trading on Tuesday, shares of Pfizer were yielding above the 6% mark based on its quarterly dividend (annualized to $1.68), with the stock changing hands as low as $27.91 on the day. Dividends are particularly important for investors to consider, because historically speaking dividends have provided a considerable share of the stock market's total return.

Amid a challenging market environment, one of your best bets could be to target biotech stocks to buy. Yes, the sector can be volatile because much hinges on underlying breakthroughs.

Pfizer Pfizer (NYSE: PFE) reported its Q1 results last week, with revenues and earnings beating the street estimates. The company reported revenue of $14.9 billion and an adjusted profit of $0.82 per share, compared to the consensus estimates of $14.0 billion and $0.52, respectively.